Removal of Federal DATA Waiver (X-Waiver) Requirement

Posted in Latest News on February 2, 2023.

On December 29, 2022, the Consolidated Appropriations Act of 2023 was signed and removes the federal requirement for practitioners to submit a Notice of Intent (NOI), or a waiver application, to prescribe medications like buprenorphine, for the treatment of opioid use disorder (OUD). With this provision, and effective immediately, the Substance Abuse and Mental Health Services Administration (SAMHSA) will no longer be accepting waiver applications.

All practitioners who have a current United States Drug Enforcement Administration (DEA) registration that includes Schedule III authority, may now prescribe buprenorphine for OUD in their practice. There are no longer any limits or patient caps on the number of patients a prescriber may treat for OUD with buprenorphine.

Dispensers are no longer required to enter the “X-Waiver” number into the Prescription Drug Monitoring Program as all prescriptions for buprenorphine only require a standard DEA registration number.

SAMHSA and the DEA are actively working on implementation of a separate provision of the Act related to training requirements for DEA registration that becomes effective June 2023.

For continued updates, please visit SAMHSA’s website.

More Latest News

2023 Annual Long-Range Planning Meeting
December 21, 2022

The Division of Medical Quality Assurance has announced the 2023 Annual Long-Range Planning meeting. Click here for more information. Continue reading

Governor DeSantis declares State of Emergency for Subtropical Storm Nicole
November 7, 2022

On Monday, November 7, 2022, Governor Ron DeSantis declared a State of Emergency to prepare for Subtropical Storm Nicole. Continue reading